Associated tags: Biotechnology, Therapy, Diabetes, Pharmaceutical industry, Health, Pharmaceutical, Gastrointestinal disease, Neurology, Research, Obesity, DSM-IV codes
Locations: NEW YORK, UNITED STATES, NORTH AMERICA
Retrieved on:
Wednesday, September 27, 2023
Biotechnology,
Diabetes,
Health,
Pharmaceutical,
Clinical Trials,
Obesity,
Type 2 diabetes,
Therapy,
Public,
Cardiovascular disease,
Weight loss,
PYY,
Research and development,
Development,
Type 2,
CCK,
Patient,
Physician,
Bariatric surgery,
Research,
GI,
Safety,
Pharmaceutical industry The trial, K-757 P006 , aims to demonstrate the weight-loss efficacy, safety, and tolerability of these novel agents for patients with obesity, a growing epidemic in the United States.
Key Points:
- The trial, K-757 P006 , aims to demonstrate the weight-loss efficacy, safety, and tolerability of these novel agents for patients with obesity, a growing epidemic in the United States.
- Weight loss can play an important role in helping patients living with obesity to manage serious health consequences including Type 2 diabetes, cardiovascular disease, and high cholesterol.
- It has been well demonstrated that oral treatments are highly preferred both by patients and physicians.
- They are the only known oral nutrient receptor agonists being studied for the treatment of obesity.
Biotechnology,
Neurology,
Diabetes,
Health,
Pharmaceutical,
GSK plc,
Obesity,
University,
Therapy,
Allianz,
International Center,
LetterOne,
DSM-IV codes,
Multimedia,
Franz Humer,
International Centre for Missing & Exploited Children,
University of Innsbruck,
Temasek,
Gastrointestinal disease,
INSEAD,
Drug discovery,
Diageo,
Pharmaceutical industry,
Management Key Points:
- View the full release here: https://www.businesswire.com/news/home/20230606005244/en/
Dr. Humer brings decades of managerial experience to the Kallyope board.
- He has served as chair of several international companies and currently serves as:
Member of the board of directors, Allogene Therapeutics
Member of the board of directors, Emil Frey Holdings
Member of the board of directors, LetterOne
“Dr.
- It is an honor to welcome him to Kallyope as chair of our board of directors,” said Jay Galeota, president and CEO, Kallyope.
- “I am privileged to join the Kallyope board of directors as chair at this exciting time for the company,” said Dr. Humer.
Other Health,
Environment,
Other Philanthropy,
Other Science,
Research,
Socially Responsible Investing,
Environmental Issues,
Environmental, Social and Governance (ESG),
Foundation,
Professional Services,
Fitness & Nutrition,
Science,
Philanthropy,
General Health,
Biotechnology,
Neurology,
Diabetes,
Health,
Kwashiorkor,
Pregnancy,
Therapy,
Life,
Malnutrition,
EED,
DSM-IV codes,
Woman,
Global health,
Inflammation,
Melinda French Gates,
UNICEF,
Bill & Melinda Gates Foundation,
Mother,
Metabolism,
Gastrointestinal disease,
Child,
Adolescence,
Bill,
Stunt,
Infant,
Gastroenteritis,
Syndrome,
Disease,
Pharmaceutical industry,
Birth control The four-year agreement focuses on discovery and characterization of metabolites that can be developed and delivered to undernourished pregnant and lactating women who are experiencing environmental enteric dysfunctions (EED).
Key Points:
- The four-year agreement focuses on discovery and characterization of metabolites that can be developed and delivered to undernourished pregnant and lactating women who are experiencing environmental enteric dysfunctions (EED).
- EED is an incompletely defined syndrome of inflammation, high enteropathogen burden, reduced absorptive capacity, and reduced barrier function of the small intestine.
- Under the agreement, the foundation will provide a grant to Kallyope of $8.2 million over four years.
- Kallyope will retain rights to develop compounds derived from the identified agents as possible therapeutics in other global regions, including as supplements in low-resource nations.
